Long-Term Monitoring of AEs and Reintegrating Patients back into Community Care
The discussion focuses on protocols for monitoring long-term complications from CAR T-cell and bispecific therapies, improving patient reintegration into community care posttreatment, and enhancing communication between academic and community oncologists.
EP: 1.Importance of Collaboration between Academic and Community Centers
EP: 2.Referral Process: Streamlining and Challenges Seen
EP: 3.Referral Process: Bispecifics
EP: 4.Similarities and Differences among Bispecifics: BCMA vs non-BCMA
EP: 5.Types of Referrals and Impact of Social Factors on the Referral Process
EP: 6.Managing AEs Seen with Bispecifics
EP: 7.Referral Process: CAR T-Cell Therapy
EP: 8.CAR T: Impact of Recent Approvals on the Referral Process
Now Viewing
EP: 9.Long-Term Monitoring of AEs and Reintegrating Patients back into Community Care
EP: 10.Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMM
Video content above is prompted by the following:
- What protocols and processes do you have in place to continue monitoring and managing potential long-term complications or adverse events associated with CAR T-cell and bispecific therapy (risk of infections, etc)?
- How can we improve the reintegration of patients into community care after receiving treatment at an academic center?
- How can we improve communication between academic and community oncologists throughout the referral and treatment process?
Recent Videos
Related Content
